“Cardiotoxicity in Low-to-Moderate Cardiovascular Risk Patients Undergoing Anti-HER2 Therapy: A Prospective CMR Study”. 2025. Radiology and Oncology 59 (4): 510-21. https://www.radioloncol.com/index.php/ro/article/view/4626.